American Journal of Medicine, internal medicine, medicine, health, healthy lifestyles, cancer, heart disease, drugs

Osteoporosis in the Women’s Health Initiative: Another Treatment Gap?

bone stock

Osteoporotic fractures are associated with high morbidity, mortality, and cost.

Methods

We performed a post hoc analysis of the Women’s Health Initiative (WHI) clinical trials data to assess osteoporosis treatment and identify participant characteristics associated with utilization of osteoporosis medication(s) after new diagnoses of osteoporosis or fracture. Information from visits prior to and immediately subsequent to the first fracture event or osteoporosis diagnosis were evaluated for medication use. A full logistic regression model was used to identify factors predictive of osteoporosis medication use after a fracture or a diagnosis of osteoporosis.

Results

The median length of follow-up from enrollment to the last WHI clinic visit for the study cohort was 13.9 years. Among the 13,990 women who reported new diagnoses of osteoporosis or fracture between enrollment and their final WHI visit, and also had medication data available, 21.6% reported taking an osteoporosis medication other than estrogen. Higher daily calcium intake, diagnosis of osteoporosis alone or both osteoporosis and fracture (compared with diagnosis of fracture alone), Asian or Pacific Islander race/ethnicity (compared with White/Caucasian), higher income, and hormone therapy use (past or present) were associated with significantly higher likelihood of osteoporosis pharmacotherapy. Women with Black/African American race/ethnicity (compared with White/Caucasian), body mass index ≥30 (compared with body mass index of 18.5-24.9), current tobacco use (compared with past use or lifetime nonusers), and history of arthritis were less likely to use osteoporosis treatment.

Conclusion

Despite well-established treatment guidelines in postmenopausal women with osteoporosis or history of fractures, pharmacotherapy use was suboptimal in this study. Initiation of osteoporosis treatment after fragility fracture may represent an opportunity to improve later outcomes in these high-risk women. Specific attention needs to be paid to increasing treatment among women with fragility fractures, obesity, current tobacco use, history of arthritis, or of Black race/ethnicity.

To read this article in its entirety please visit our website.

-Maryam Sattari, MD, MS, Jane A. Cauley, DrPH, Cynthia Garvan, PhD, Karen C. Johnson, MD, MPH, Michael J. LaMonte, PhD, MPH, Wenjun Li, PhD, Marian Limacher, MD, Todd Manini, PhD, Gloria E. Sarto, MD, PhD, Shannon D. Sullivan, MD, PhD, Jean Wactawski-Wende, PhD, Rebecca J. Beyth, MD, MSc

This article originally appeared in the August 2017 issue of The American Journal of Medicine.

Comments are closed.

UA-42320404-1